

Ref: FOI/CAD/ID 3224

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

06 April 2016

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to diseases of the eye and treatment options and volumes.

The total patients treated with the following conditions:

- *Wet age-related macular degeneration (AMD)*
- *Diabetic macular oedema (DMO)*
- *Macular oedema secondary to retinal vein occlusion, branch (branch RVO)*
- *Macular oedema secondary to retinal vein occlusion, central (central RVO)*
- *Myopic choroidal neovascularization (mCNV)*

The volume of use of the following treatment options:

- *Ranibizumab*
- *Bevacizumab*
- *Aflibercept*
- *Dexamethasone intravitreal implant*
- *Fluocinolone acetonide intravitreal implant*
- *Laser Therapy*

I would like this information for the period March 2015 to February 2016, broken down by month

The Trust does not record electronically the number of patients who are treated by laser for a condition.

Please see the tables below:

| Name of Hospital Trust | Maidstone and Tunbridge Wells NHS Trust | | | | | | | | | | | | | | | | | | | | | | | | |
|--|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|---|--|--|--|--|--|--|--|--|--|--|--|--|
| Disease Description and Treatment Option | | | | | | | | | | | | | NUMBER OF PATIENTS TREATED PER MONTH (if small numbers e.g. 5 or under suppress to 5*) | | | | | | | | | | | | |
| wAMD (Wet Age Related Macular Degeneration) | Mar-15 | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | Dec-15 | Jan-16 | Feb-16 | | | | | | | | | | | | | |
| Ranibizumab | 219 | 252 | 215 | 174 | 211 | 144 | 218 | 204 | 134 | 205 | 191 | 162 | | | | | | | | | | | | | |
| Bevacizumab | | | | | | | | | | | | | | | | | | | | | | | | | |
| Aflibercept | 151 | 177 | 187 | 175 | 218 | 157 | 220 | 261 | 146 | 280 | 287 | 232 | | | | | | | | | | | | | |
| Disease Description and Treatment Option | | | | | | | | | | | | | NUMBER OF PATIENTS TREATED PER MONTH (if small numbers e.g. 5 or under suppress to 5*) | | | | | | | | | | | | |
| bRVO (Branch Retinal Vein Occlusion) | Mar-15 | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | Dec-15 | Jan-16 | Feb-16 | | | | | | | | | | | | | |
| Ranibizumab | 38 | 34 | 34 | 21 | 38 | 31 | 35 | 42 | 17 | 53 | 46 | 42 | | | | | | | | | | | | | |
| Bevacizumab | | | <5 | <5 | <5 | | | | <5 | <5 | <5 | | | | | | | | | | | | | | |
| Aflibercept | | | | | <5 | <5 | <5 | <5 | | <5 | | <5 | | | | | | | | | | | | | |
| Dexamethasone intravitreal implant | <5 | 5 | 5 | <5 | <5 | <5 | <5 | | <5 | <5 | <5 | <5 | | | | | | | | | | | | | |
| Laser therapy treatment for stated condition | | | | | | | | | | | | | | | | | | | | | | | | | |
| Disease Description and Treatment Option | | | | | | | | | | | | | NUMBER OF PATIENTS TREATED PER MONTH (if small numbers e.g. 5 or under suppress to 5*) | | | | | | | | | | | | |
| cRVO (Central Retinal Vein Occlusion) | Mar-15 | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | Dec-15 | Jan-16 | Feb-16 | | | | | | | | | | | | | |
| Ranibizumab | 23 | 25 | 19 | 14 | 23 | 23 | 30 | 30 | 17 | 32 | 25 | 14 | | | | | | | | | | | | | |
| Bevacizumab | | <5 | <5 | | | | | <5 | | <5 | | | | | | | | | | | | | | | |
| Aflibercept | <5 | <5 | <5 | 5 | 7 | 7 | 5 | 10 | <5 | 12 | 8 | 6 | | | | | | | | | | | | | |
| Dexamethasone intravitreal implant | <5 | 7 | 6 | 5 | <5 | 5 | 7 | 6 | <5 | <5 | 7 | <5 | | | | | | | | | | | | | |
| Laser therapy treatment for stated condition | | | | | | | | | | | | | | | | | | | | | | | | | |
| Disease Description and Treatment Option | | | | | | | | | | | | | NUMBER OF PATIENTS TREATED PER MONTH (if small numbers e.g. 5 or under suppress to 5*) | | | | | | | | | | | | |
| DMO (Diabetic Macular Oedema) | Mar-15 | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | Dec-15 | Jan-16 | Feb-16 | | | | | | | | | | | | | |
| Ranibizumab | 76 | 78 | 64 | 55 | 73 | 66 | 90 | 104 | 59 | 111 | 101 | 92 | | | | | | | | | | | | | |
| Bevacizumab | | | | | | | | <5 | <5 | <5 | | | | | | | | | | | | | | | |
| Aflibercept | | | | | | | | | | 7 | 12 | 26 | | | | | | | | | | | | | |
| Dexamethasone intravitreal implant | <5 | | | | | | | | <5 | | | <5 | | | | | | | | | | | | | |

| | | | | | | | | | | | | |
|---|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Fluocinolone acetonide intravitreal implant | 6 | <5 | <5 | <5 | <5 | | <5 | <5 | <5 | <5 | | |
| Laser therapy treatment for stated condition | | | | | | | | | | | | |
| Disease Description and Treatment Option | NUMBER OF PATIENTS TREATED PER MONTH (if small numbers e.g. 5 or under suppress to 5*) | | | | | | | | | | | |
| mCNV (myopic choroidal neovascularization) | Mar-15 | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | Dec-15 | Jan-16 | Feb-16 |
| Ranibizumab | | | | | | | | <5 | | | | |
| Bevacizumab | | | | <5 | | | <5 | | <5 | | | |
| Aflibercept | | | | | | | | | | | | |

| | | | | | | | | | | | | |
|--|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Name of treatment Hospital | Maidstone and Tunbridge Wells NHS Trust | | | | | | | | | | | |
| Disease Description | Volume of Injections (number of vials used) given by indication by month | | | | | | | | | | | |
| wAMD (Wet Age Related Macular Degeneration) | Mar-15 | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | Dec-15 | Jan-16 | Feb-16 |
| Ranibizumab | 236 | 273 | 227 | 185 | 219 | 154 | 230 | 218 | 144 | 226 | 206 | 174 |
| Bevacizumab | | | | | | | | | | | | |
| Aflibercept | 169 | 196 | 205 | 195 | 235 | 169 | 240 | 290 | 160 | 305 | 310 | 256 |
| Disease Description | Volume of Injections (number of vials used) given by indication by month | | | | | | | | | | | |
| bRVO (Branch Retinal Vein Occlusion) | Mar-15 | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | Dec-15 | Jan-16 | Feb-16 |
| Ranibizumab | 39 | 35 | 34 | 21 | 39 | 31 | 35 | 43 | 17 | 53 | 46 | 43 |
| Bevacizumab | | | 1 | 2 | 1 | | | | 1 | 1 | 1 | |
| Aflibercept | | | | | 2 | 1 | 2 | 1 | | 1 | | 1 |
| Dexamethasone intravitreal implant | 3 | 5 | 6 | 3 | 3 | 1 | 3 | | 2 | 1 | 1 | 3 |
| Disease Description | Volume of Injections (number of vials used) given by indication by month | | | | | | | | | | | |
| cRVO (Central Retinal Vein Occlusion) | Mar-15 | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | Dec-15 | Jan-16 | Feb-16 |
| Ranibizumab | 23 | 26 | 21 | 15 | 23 | 23 | 31 | 32 | 18 | 32 | 25 | 14 |
| Bevacizumab | | 1 | 1 | | | | | 1 | | 2 | | |
| Aflibercept | 1 | 2 | 2 | 5 | 7 | 7 | 5 | 10 | 1 | 12 | 8 | 6 |
| Dexamethasone intravitreal implant | 4 | 8 | 6 | 5 | 3 | 5 | 7 | 6 | 2 | 1 | 7 | 4 |

